Prescient Therapeutics Ltd (ASX:PTX) Share Price & Analysis
(ASX:PTX) Share Price Chart
About (ASX: PTX)
Prescient Therapeutics is a clinical-stage oncology company listed on the Australian Securities Exchange (ASX: PTX), dedicated to developing innovative targeted therapies to improve cancer treatment outcomes. The company’s primary focus is on creating advanced therapeutic approaches that address unmet medical needs in oncology, with a diverse pipeline of technologies developed in collaboration with world-leading research institutions such as Yale, UPenn, Oxford, Moffitt, and Peter MacCallum Cancer Centre.
The company’s lead asset, PTX-100, is a first-in-class targeted therapy that disrupts the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. This innovative approach has received significant regulatory recognition, including Fast Track Designation, Orphan Drug Designation, and Investigational New Drug (IND) status from the US FDA for T cell lymphomas. Currently, PTX-100 is undergoing a Phase 2a clinical study in refractory/relapsed Cutaneous T Cell Lymphoma, representing a promising potential treatment for patients with limited options.
Beyond PTX-100, Prescient Therapeutics is advancing cutting-edge cell therapy technologies like CellPryme and OmniCAR. CellPryme is a high-performance cell therapy enhancement platform designed to improve CAR-T efficacy, while OmniCAR is a modular, universal CAR platform that aims to overcome challenges in conventional CAR-T therapy. These technologies demonstrate the company’s commitment to developing innovative, flexible approaches that could potentially transform cancer treatment by providing more effective, safer, and more reliable cellular immunotherapies.